It has been shown that advanced pancreatic cancer with biallelic loss of BRCA1 and BRCA2 had a higher median tumor mutation burden than wild type tumors with the consequent possible higher sensitivity to ICIs [89]. This evidence concerns the gene BRCA2 and pancreatic neoplasm.